Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics (KPTI) reported an insider equity award for its President and CEO, Richard Paulson, on 10/15/2025. He received 114,285 restricted stock units at $0 under the company’s 2022 Equity Incentive Plan. The RSUs convert into common stock on a one-for-one basis and vest 100% on December 31, 2026. Following the grant, Paulson’s beneficial ownership totaled 198,331 common shares, held directly. He is also listed as a director.
Karyopharm Therapeutics (KPTI) reported an insider equity grant on a Form 4. EVP, Chief Development Officer Stuart Poulton received 39,682 restricted stock units (RSUs) on 10/15/2025 under the company’s 2022 Equity Incentive Plan at a reported price of $0. The RSUs convert to common stock on a one‑for‑one basis and vest 100% on December 31, 2026.
Following the grant, his direct beneficial ownership was 67,392 shares. This filing documents a routine equity award to a company officer.
Karyopharm Therapeutics (KPTI) reported a Form 4 showing Chief Accounting Officer Kristin Abate received 12,799 restricted stock units (RSUs) on October 15, 2025 at a stated price of $0. The RSUs convert into common stock on a one-for-one basis.
According to the award terms, 2,799 RSUs vest in two equal annual installments beginning October 31, 2026, and 10,000 RSUs vest 100% on October 15, 2026. Following this award, Abate beneficially owned 22,845 shares, reported as Direct (D) ownership.
Karyopharm Therapeutics (KPTI) completed a set of financing transactions. The company issued 9.00% senior secured convertible notes in two series: $15.0 million aggregate principal amount due 2028 and $103.5 million aggregate principal amount due 2029. It also borrowed $12.5 million under its existing credit and guaranty agreement.
The company entered into indentures for each note series with Wilmington Savings Fund Society as trustee and collateral agent and executed related registration rights agreements with term loan lenders. Exhibits include a first amendment and waiver to the credit agreement, a note purchase agreement, exchange agreements, warrant forms, a pre-funded warrant form, and a sixth amendment to the revenue interest financing agreement.
Shares outstanding were 15,926,939 as of October 14, 2025, assuming no exercise of pre-funded warrants or warrants and no conversions of the new convertible notes.
Karyopharm Therapeutics, Inc. disclosed an amendment and related licensing activity centered on its oncology drug selinexor. Under an Amendment No. 4 dated August 7, 2025, Karyopharm granted Berlin-Chemie AG (an affiliate of the Menarini Group) a non-exclusive license to develop and an exclusive license to commercialize selinexor for human oncology indications across Europe (including the United Kingdom), Latin America, certain Middle East and Africa regions and other specified countries. The filing also references exchange transactions involving pre-funded warrants and warrants to purchase common stock (including warrants for an aggregate of 2,502,151 shares and pre-funded warrants for 552,164 and 1,404,087 shares) and notes a correction to a prior 10-Q paragraph. The notice was accompanied by a press release dated October 8, 2025.
Karyopharm Therapeutics (KPTI) reported an insider transaction by its Chief Accounting Officer, Kristin Abate. On 10/01/2025, Abate sold 362 shares of common stock at a weighted average price of $6.296. Following the sale, she beneficially owned 10,046 shares directly.
According to the filing, the broker-assisted sale was executed under a durable automatic sale instruction plan adopted on May 27, 2021, to satisfy withholding taxes upon the vesting of PSUs, and does not represent a discretionary trade.
Richard A. Paulson, President, CEO and a director of Karyopharm Therapeutics (KPTI), reported the vesting of 2,800 performance-based restricted stock units (PSUs) on September 12, 2025. These PSUs were granted in February 2023 and were earned after the Compensation Committee certified completion of enrollment in the company’s Phase 3 SENTRY trial; each earned PSU represents the contingent right to one share and vested upon certification. Following vesting, a broker-assisted sale executed under an automatic sale instruction plan sold 1,257 shares on September 15, 2025 at $6.43 per share to satisfy withholding tax obligations. After these transactions, the reporting person beneficially owned 84,046 shares.
Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics (KPTI), reported that 612 performance-based restricted stock units (PSUs) were certified as earned and vested following achievement of a clinical enrollment milestone for the company’s Phase 3 SENTRY trial, converting into the contingent right to the same number of common shares. To satisfy tax withholding on the vested PSUs, the reporting person executed a broker-assisted sale of 234 shares at an average price of $6.43, leaving beneficial ownership of 21,425 shares.
Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics (KPTI), reported the vesting of 888 performance-based restricted stock units (PSUs) on 09/12/2025 after the company certified completion of enrollment in its Phase 3 SENTRY trial. Each PSU converts to one share, increasing his beneficial ownership to 28,111 shares. On 09/15/2025 he executed an automatic, broker-assisted sale of 401 shares at $6.43 to cover withholding taxes, leaving 27,710 shares beneficially owned. The PSUs were originally granted in February 2023 and vested upon certification by the Compensation Committee. The Form 4 was signed by an attorney-in-fact on 09/16/2025.
Insider filings show that Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics (KPTI), had performance-based restricted stock units (PSUs) certified as earned and vested on September 12, 2025. The certification converted 945 PSUs into the contingent right to receive 945 shares of common stock, increasing her beneficial holdings to 29,798 shares. Three days later, on September 15, 2025, Rangwala executed a broker-assisted sale of 408 shares at $6.43 per share under an automatic sale instruction plan to satisfy withholding tax liabilities related to the PSU vesting, leaving her with 29,390 shares beneficially owned.